This morning, Goldman Sachs raised its EPS estimates on shares of Cardinal Health (NYSE:CAH) through 2012 as its generic drugs business continues to perform well. In the report, Goldman raised its price target to $43 while maintaining its neutral rating.
Shares of Cardinal Health were lower, despit the report, falling 1.7% so far.
And Citigroup upgraded shares of Hospira (HSP) from sell to hold as the market is already pricing in the possibility of disappointing earnings. With the upgrade, Citigroup set its price target at $52 per share.
Shares of Hospira were lower on the news, falling 0.5% today.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.